DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,199,093 | +3.4% | 16,925 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $4,062,000 | -4.8% | 16,925 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $4,265,777 | -6.7% | 16,925 | -1.8% | 0.00% | 0.0% |
| Q4 2022 | $4,573,717 | -2.4% | 17,232 | -5.0% | 0.00% | -25.0% |
| Q3 2022 | $4,686,000 | +1.9% | 18,142 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $4,599,000 | -13.6% | 18,142 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $5,322,000 | -10.8% | 18,142 | 0.0% | 0.00% | -25.0% |
| Q4 2021 | $5,969,000 | +7.9% | 18,142 | -0.1% | 0.00% | 0.0% |
| Q3 2021 | $5,531,000 | +13.5% | 18,167 | 0.0% | 0.00% | +33.3% |
| Q2 2021 | $4,875,000 | +19.2% | 18,167 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $4,089,000 | -1.4% | 18,167 | -2.7% | 0.00% | 0.0% |
| Q4 2020 | $4,147,000 | -12.2% | 18,667 | -14.9% | 0.00% | -25.0% |
| Q3 2020 | $4,725,000 | +14.9% | 21,942 | -5.7% | 0.00% | 0.0% |
| Q2 2020 | $4,114,000 | +26.4% | 23,267 | -1.0% | 0.00% | 0.0% |
| Q1 2020 | $3,254,000 | -9.8% | 23,510 | 0.0% | 0.00% | +33.3% |
| Q4 2019 | $3,608,000 | -6.1% | 23,510 | -11.6% | 0.00% | 0.0% |
| Q3 2019 | $3,843,000 | -99.4% | 26,610 | -99.4% | 0.00% | -99.4% |
| Q2 2019 | $656,570,000 | +5.6% | 4,593,968 | -2.5% | 0.53% | +4.1% |
| Q1 2019 | $621,731,000 | +28.5% | 4,709,368 | +0.4% | 0.51% | +15.1% |
| Q4 2018 | $483,733,000 | -7.5% | 4,690,968 | -2.5% | 0.44% | +10.8% |
| Q3 2018 | $522,743,000 | +9.4% | 4,810,818 | -0.6% | 0.40% | +4.7% |
| Q2 2018 | $477,771,000 | -4.6% | 4,841,618 | -5.4% | 0.38% | -5.4% |
| Q1 2018 | $501,037,000 | +4.0% | 5,117,323 | -1.4% | 0.40% | +8.3% |
| Q4 2017 | $481,942,000 | +7.7% | 5,192,223 | -0.5% | 0.37% | +3.6% |
| Q3 2017 | $447,525,000 | +1.0% | 5,217,123 | -0.6% | 0.36% | -3.7% |
| Q2 2017 | $443,113,000 | +1.6% | 5,250,773 | +3.0% | 0.37% | +0.8% |
| Q1 2017 | $436,137,000 | +7.3% | 5,099,223 | -2.3% | 0.37% | +2.8% |
| Q4 2016 | $406,424,000 | -9.3% | 5,221,273 | -8.6% | 0.36% | -14.3% |
| Q3 2016 | $448,031,000 | -33.3% | 5,715,408 | -14.1% | 0.42% | -36.6% |
| Q2 2016 | $672,070,000 | -3.8% | 6,654,158 | -9.7% | 0.66% | -2.9% |
| Q1 2016 | $698,787,000 | +1.4% | 7,366,508 | -0.7% | 0.68% | +1.2% |
| Q4 2015 | $689,152,000 | -13.0% | 7,419,808 | -20.2% | 0.68% | -15.2% |
| Q3 2015 | $792,160,000 | -7.5% | 9,296,558 | -7.1% | 0.80% | +3.1% |
| Q2 2015 | $856,752,000 | -5.9% | 10,009,951 | -6.7% | 0.77% | -7.9% |
| Q1 2015 | $910,510,000 | +6.5% | 10,724,501 | +7.5% | 0.84% | +5.7% |
| Q4 2014 | $855,037,000 | +230368.2% | 9,975,933 | +204199.3% | 0.79% | – |
| Q3 2014 | $371,000 | – | 4,883 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |